Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

The Engagement Between MDSCs and Metastases: Partners in Crime

(2020) Rosalinda Trovato et al.   Frontiers in Oncology

Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics

(2020) Hamad Alshetaiwi et al.   Science Immunology

The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies

(2020) Andriy Zhylko et al.   Cancers

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors

(2019) Robin Parihar et al.   Cancer Immunology Research

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

(2019) Mohamed-Reda Benmebarek et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression

(2019) Antonino Bruno et al.   Frontiers in Immunology

Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease

(2019) Giada Mondanelli et al.   Frontiers in Immunology

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

(2019) Eleni-Kyriaki Vetsika et al.   Cells

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

(2018) Luke Piggott et al.   CLINICAL CANCER RESEARCH

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

(2018) Viktor Fleming et al.   Frontiers in Immunology

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

(2018) Pradip Bajgain et al.   Journal for ImmunoTherapy of Cancer

Engineering CAR-T Cells for Improved Function Against Solid Tumors

(2018) Michael A. Morgan et al.   Frontiers in Immunology

Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes

(2017) Sílvia Casacuberta-Serra et al.   IMMUNOLOGY AND CELL BIOLOGY

Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis

(2017) Elham Safarzadeh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Chimeric antigen receptor T cell therapy: 25years in the making

(2016) Saar Gill et al.   BLOOD REVIEWS

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody

(2016) George A. Dominguez et al.   CLINICAL CANCER RESEARCH

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers

(2016) Roni Allaoui et al.   Nature Communications

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment

(2016) Manuela Liguori et al.   Oncotarget

Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells

(2015) Thomas Condamine et al.   Annual Review of Medicine

An overview of triple-negative breast cancer

(2015) Pankaj Kumar et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

(2015) Kyriakos P. Papadopoulos et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

c-FLIP Protects T Lymphocytes from Apoptosis in the Intrinsic Pathway

(2015) Ming-Xiao He et al.   JOURNAL OF IMMUNOLOGY

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

(2015) Murugan Kalimutho et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

(2014) Jonathan D. Graves et al.   CANCER CELL

BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity

(2014) Y. Cao et al.   CANCER RESEARCH

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis

(2014) Thomas Condamine et al.   JOURNAL OF CLINICAL INVESTIGATION

A Tumor Environment Responsive Doxorubicin-Loaded Nanoparticle for Targeted Cancer Therapy

(2014) Qian Zhu et al.   MOLECULAR PHARMACEUTICS

Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor

(2014) Ann M Leen et al.   MOLECULAR THERAPY

Myeloid-derived suppressor cells in breast cancer

(2013) Joseph Markowitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

(2013) Sunil Sharma et al.   INVESTIGATIONAL NEW DRUGS

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas

(2013) Krzysztof Majchrzak et al.   Neurologia i Neurochirurgia Polska

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

(2013) Andres Forero-Torres et al.   Cancer Medicine

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

(2012) Caio M. Rocha Lima et al.   CANCER INVESTIGATION

A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells

(2012) Yan Zhang et al.   CELL RESEARCH

Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors

(2012) Melinda S. Merchant et al.   JOURNAL OF CLINICAL ONCOLOGY

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

(2012) David E. Gilham et al.   TRENDS IN MOLECULAR MEDICINE

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche

(2012) Jaclyn Sceneay et al.   OncoImmunology

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

(2010) M. G. Lechner et al.   JOURNAL OF IMMUNOLOGY

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

(2009) Johanna K. Morales et al.   BREAST CANCER RESEARCH AND TREATMENT

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

(2009) Nabil Ahmed et al.   MOLECULAR THERAPY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY